Morgan Stanley analyst Robert Davies raised the firm’s price target on Fresenius Medical (FMS) to EUR 46 from EUR 43 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Launches EUR 1 Billion Share Buyback Program
- Fresenius Medical announces first tranche of share buyback program
- Fresenius Medical price target lowered to EUR 48 from EUR 50 at Deutsche Bank
- Hold Rating Maintained for Fresenius Medical Care Amidst Flat US Growth and Downward Financial Adjustments
- Fresenius Medical Care Reports Modest Growth in 2025 Earnings